Quality of Life, Recombinant TSH (Thyrogen) and Thyroid Cancer

• Status: Completed
• Trial end date: 2012-02-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate quality of life in patients after 10 days pause of thyroid medication (Liothyronine) compared to treatment with recombinant TSH (Thyrogen) before radioiodine uptake and treatment in a double-blinded, randomised cross-over design.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Copenhagen University Hospital at Herlev
• Collaborator: Odense University Hospital

Criteria

Inclusion Criteria:

• Follicular or papillary thyroid cancer

Exclusion Criteria:

• < 18 or > 75 years old

• Pregnant or lactating women